论文部分内容阅读
目前,尚无关于大剂量或小剂量同期放化疗(CRT)之间比较的随机研究。该文作者将7219例临床Ⅲ期或Ⅳ期头颈鳞癌(HNSCC)患者纳入研究,并随机分为2组,第1组包括接受小剂量同期CRT(n=1575)的患者,第2组包括接受大剂量同期CRT(n=5644)的患者。结果 :Cox回归分析显示,年龄≥65岁、男性、Charlson合并症指数(CCI)评分高、放疗(RT)时间≥7.5周、临床分级Ⅳ期、口腔癌、吸烟史和顺铂总剂量≥240mg/m2成为影响总生存率(OS)的独
At present, there is no randomized study on the comparison between high-dose or low-dose concurrent chemoradiotherapy (CRT). The authors enrolled 7,219 patients with stage III or IV HNSCC who were randomized into 2 groups, group 1 included patients who received low-dose CRT (n = 1575), group 2 included Patients receiving high-dose concurrent CRT (n = 5644). Results: The Cox regression analysis showed that the patients with the age of 65 or older had higher Charlson’s complication index (CCI) score, radiotherapy (RT) ≥7.5 weeks, clinical stage Ⅳ, oral cancer, smoking history and the total dose of cisplatin ≥240mg / m2 To affect the overall survival rate (OS) alone